Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques

29 Apr 2023

Abstract excerpt

Since early 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally infecting over 500 million people and causing over 6 million deaths. The massive worldwide immunisation programmes and the arising clinical trial data present a unique opportunity to compare the vaccines and various delivery platforms (i.e. viral vector platform, mRNA platform and virus-like particle platform). As...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37120453
DOI: 10.1038/s41392-023-01425-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaquesPMID 37120453Read ↗

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read ↗

Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Semantic proximity Read ↗

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity Read ↗

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity Read ↗

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccinesSemantic proximity Read ↗

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaquesSemantic proximity Read ↗

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Semantic proximity Read ↗

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read ↗

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read ↗

A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 delta variant in transgenic K18-hACE2 miceSemantic proximity Read ↗

A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 MiceSemantic proximity Read ↗

A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.